New Strategies, Targets in Triple-Negative Breast Cancer
This video with Stacy Moulder, MD, highlights efforts to identify various subtypes and molecular targets in triple-negative breast cancer, which could lead to treatment options with already approved agents.
In this video, Stacy Moulder, MD, of MD Anderson Cancer Center, highlights efforts to identify various subtypes and molecular targets in triple-negative breast cancer, an often difficult-to-treat disease, which could potentially lead to treatment options already approved by the US Food and Drug Administration.
Dr. Moulder also discusses the challenge in finding patients with triple-negative disease that will have durable responses to chemotherapy, and the need for better molecular diagnostic assays to identify those patients who will be resistant to cytotoxic agents.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
